🇺🇸 FDA
Patent

US 7655685

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61KA61K31/415A61P

Quick answer

US patent 7655685 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
58
CPC classes
A61K, A61K31/415, A61P, A61P1/00, A61P1/16